AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 16 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - A vaccine based on Mycobacterium bovis bacillus Calmette-Guerin (BCG) can improve the immune response to tuberculosis infection, researchers say.
"Alveolar macrophages are likely the first cell type to encounter Mycobacterium tuberculosis in a pulmonary infection, resulting in the production of chemokines," according to Mark J. Lyons and colleagues at Texas A&M University in College Station, Texas, and the National Cancer Institute in Frederick, Maryland.
A BCG-based vaccine improved M. tuberculosis-specific macrophage activity in an animal model, Lyons and coauthors reported.
The researchers collected alveolar macrophages from vaccinated and untreated guinea pigs, and exposed them to M. tuberculosis in culture for up to 24 hours. They measured cellular expression and production of interleukin (IL)-8 and monocyte chemoattractant protein 1 (MCP-1), two cytokines that play key roles in the immune response to infection, according to the report.
Macrophages from vaccinated guinea pigs expressed higher postinfection levels of IL-8 mRNA and produced greater amounts of IL-8 protein than cells from untreated animals, study data showed. However, vaccination had no significant effect on macrophage MCP-1 mRNA expression or protein output.
Cells harvested ...
Source: HighBeam Research, Mycobacterium bovis BCG inoculation may improve early...